U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07829276) titled 'Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia' on Sept. 14.
Brief Summary: In a prospective, multicenter, real-world setting, the efficacy and safety of 3mg low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the primary prevention of febrile neutropenia (FN) after chemotherapy in cancer patients were verified to address the two major clinical pain points of current fixed 6mg dose, namely economic burden and adverse reactions.
Study Start Date: Nov. 01
Study Type: OBSERVATIONAL
Condition:
Malignant Tumor
Recruitment Statu...